<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Disponibilidad de Pembrolizumab 25 mg/mL, código 1-11-41-0125

Simple item page
dc.contributor.authorCaja Costarricense de Seguro Social. Dirección de Farmacoepidemiología
dc.date.accessioned2025-03-17T16:38:01Z
dc.date.available2025-03-17T16:38:01Z
dc.date.issued2025-03-12
dc.descriptionCIRCULAR
dc.description.abstractPembrolizumab 25 mg/mL
dc.description.sponsorshipCCSS
dc.identifier.otherDFE-AFEC-0331-2025
dc.identifier.urihttp://hdl.handle.net/20.500.11764/4836
dc.language.isoes
dc.publisherCCSS
dc.subjectPEMBROLIZUMAB
dc.subjectCANCER RENAL
dc.subjectMELANOMA MALIGNO
dc.subjectCANCER DE MAMA
dc.subjectCANCER DE CERVIX
dc.titleDisponibilidad de Pembrolizumab 25 mg/mL, código 1-11-41-0125
dc.title.alternativeDFE-AFEC-0331-2025
dc.typeWorking Paper

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Circular DFE-AFEC-0331-2025 Disponibilidad de pembrolizumab 25 mg mL código 1-11-41-0125.pdf
Size:
136.44 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
26 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Farmacoepidemiología